The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.
 
Josephine Lopes Cardozo
No Relationships to Disclose
 
Caroline Drukker
No Relationships to Disclose
 
Marjanka Schmidt
No Relationships to Disclose
 
Laura van 't Veer
Employment - Agendia
Leadership - Agendia
Stock and Other Ownership Interests - Agendia
 
Annuska Glas
Employment - Agendia
Patents, Royalties, Other Intellectual Property - Agendia
 
Anke Witteveen
Employment - Agendia
Stock and Other Ownership Interests - Agendia
 
Fatima Cardoso
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; GE Healthcare; Genentech; GlaxoSmithKline; Macrogenics; Medscape; Merck Sharp & Dohme; Merus; Mundipharma; Mylan; Novartis; Pfizer; Pierre Fabre; Prime Oncology; Roche; Samsung Bioepis; Sanofi; Seagen; Teva
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Debiopharm Group; Immunomedics; Immutep; Lilly; Menarini; MSD; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche/Genentech (Inst); Servier (Inst); Synthon (Inst)
Other Relationship - EU Cancer Mission Board; Oncolytics
 
Coralie Poncet
No Relationships to Disclose
 
Emiel J. Rutgers
No Relationships to Disclose